Every patient eventually asks the same question. Not how the drug works, not what the side effects are, not what the blood tests will show. The question that sits underneath all of those:
"What happens when I stop?"
For most treatments used in secondary hypogonadism, the honest answer is: we don't know. Not because the question is unanswerable. Because nobody funded the study.
The Structural Asymmetry
A 2025 scoping review in BMC Medical Research Methodology identified every randomized controlled trial ever conducted on drug discontinuation. Across all of medicine — every drug class, every disease — they found 103 RCTs. To put that in perspective, over 400,000 RCTs were registered on ClinicalTrials.gov by the end of 2024.
The authors wrote what should be obvious but apparently isn't:
"Scientific evidence supporting this approach remains limited — especially when compared to the extensive research on initial drug prescribing." — BMC Medical Research Methodology, 2025
Of those 103 trials, 58% didn't state a hypothesis. Only 48.5% used non-inferiority designs — the statistically appropriate framework for most discontinuation questions. The top motivation for studying discontinuation was "doubts about the benefit of the drug" (53.4%), not patient welfare after stopping.
This isn't a gap in knowledge. It's a structural feature of how medical evidence is produced. The FDA requires efficacy data for approval — data collected during treatment. Post-marketing surveillance monitors adverse events during treatment. Weight loss studies measure weight during treatment. Nobody requires, funds, or systematically collects data on what happens after.
Medicine builds on-ramps. It doesn't build exits.
Five Treatments, Five Off-Ramps, Five Different Levels of Darkness
In secondary hypogonadism, the asymmetry is stark. Five treatment modalities exist. Each acts at a different level of the HPG axis. Each has a fundamentally different pharmacological rationale for what should happen when discontinued. And the evidence for what actually happens ranges from moderate to literally zero.
| Treatment | HPG Level | What Should Happen | What We Know | Evidence |
|---|---|---|---|---|
| TRT | Gonadal replacement | T drops, axis recovers in months | Confirmed. T drops in days. Symptoms return within 3 months. HPTA recovery 3–6 months. Exercise during treatment → 10× maintained response. | Moderate |
| hCG | Leydig cell stimulation | Pituitary resumes, T returns to baseline | Pituitary recovery ~1 month. No Leydig desensitization at therapeutic doses. Fertility preserved. Returns to broken baseline in organic secondary HH. | Low-Moderate |
| SERMs | Pituitary stimulation | Restored GnRH pulsatility fades, T falls | "Legacy effect": T stays elevated ~1 week after drug clearance. T returns to baseline ~1 month. No long-term follow-up. Zero prospective data. | Very Low |
| GLP-1 RAs | Metabolic restoration | Weight regains → metabolic trap re-engages → T falls | Weight regain confirmed: 50–67% within 1 year. Metabolic rebound confirmed: +5.6 kg, +0.25% HbA1c. Testosterone trajectory: zero data. | Zero |
| AAS Recovery | Post-supraphysiological | HPG axis slowly recovers, Leydig cells may not | LH recovery ~12 months. Inhibin B ~21 months. INSL3 never fully recovers — 33% below controls. PCT accelerates speed but not long-term outcomes. | Moderate |
A pattern emerges: the oldest, crudest treatment (TRT — simple replacement) has the most discontinuation data. The newest, most pharmacologically sophisticated treatment (GLP-1 RAs) has none. And the treatment that 58.8% of real-world patients receive — combination therapy — has zero discontinuation data because it has zero RCTs of any kind.
The GLP-1 Void
This is the most consequential gap on the table. GLP-1 receptor agonists are the fastest-growing drug class in history. They restore testosterone in obese men by breaking the metabolic trap — three meta-analyses confirm increases of 1.3–1.4 ng/mL during treatment. But treatment is indefinite, and discontinuation is common: a 2025 JAMA analysis found high rates of discontinuation and reinitiation in real-world use.
When patients stop:
- Weight regain — confirmed. 50–67% of lost weight returns within 1 year (Berg, Obesity Reviews 2025). An eClinicalMedicine meta-analysis (18 RCTs, n=3,771) quantified the rebound: +5.63 kg, +0.25% HbA1c, with lipid and blood pressure reversal.
- Metabolic markers — confirmed. The Cleveland Clinic real-world study (~8,000 patients, March 2026) showed less dramatic regain in practice — because many patients restart or switch.
- Testosterone trajectory — zero data. Not low-quality data. Not conflicting data. No data. The eClinicalMedicine meta-analysis across 18 RCTs didn't report testosterone. The Cleveland Clinic study across 8,000 patients didn't measure it.
If weight regains and the metabolic trap re-engages, testosterone should fall back to hypogonadal levels. That's the logical inference from everything we know about the metabolic trap's five interlocking loops. But "should" is not evidence. Nobody has verified it.
What Bariatric Surgery Tells Us
The closest proxy comes from an older intervention with longer follow-up: bariatric surgery. Weight loss is more durable after surgery than after GLP-1 cessation, but weight regain still occurs — and when it does, we can watch what happens to testosterone in real time.
Total testosterone: +84.1% surgery vs +9.6% medical (P=0.008). Free testosterone: +47.4% vs −2.2% (P=0.013). Sustained at 5 years — because weight loss was sustained (−19.9% body weight).
Free testosterone normalization: 27% → 80% at 2 years → 67% at 5 years. Free T: 0.17 → 0.34 → 0.27 nmol/L. The decline from year 2 to year 5 directly correlated with weight regain during the same period. This is the clearest real-time demonstration in the literature: weight regain tracks testosterone decline.
55% of men remained hypogonadal despite surgical weight loss. Those who normalized had higher baseline testosterone (235 vs 184 ng/dL, P=0.007) and greater BMI reduction. Weight loss alone is insufficient for men with a fragile axis.
The proxy argument assembles from these three data points:
- Weight loss → testosterone recovery: established across multiple studies and meta-analyses.
- Weight regain → testosterone decline: directly demonstrated in Teen-LABS (80% → 67% normalization tracks weight trajectory).
- GLP-1 weight regain is faster and more complete than bariatric: 50–67% regained within 1 year versus gradual partial regain over 5 years after surgery.
The logical inference: GLP-1 testosterone decline after cessation is at least as rapid as what bariatric surgery shows. Probably faster. But nobody has measured it.
And there's a darker implication: the 55% of men whose testosterone never normalized even with bariatric weight loss — the fragile axis phenotype — would face GLP-1 discontinuation from a doubly broken position. Metabolic rebound plus constitutional HPG vulnerability. For these men, stopping GLP-1 therapy may not mean returning to their pre-treatment state. It may mean something worse.
The SERM Cliff
Enclomiphene — the most prescribed non-TRT intervention in US men's health clinics — has exactly one pharmacokinetic study addressing discontinuation. Wiehle 2013 showed testosterone and LH remain elevated for approximately one week after the last dose, reflecting briefly sustained GnRH pulsatility. This is called the "legacy effect."
After that one week: nothing. No prospective study has followed men beyond drug clearance. Clinical consensus — based on pharmacological reasoning, not data — estimates return to baseline within approximately one month. But clinical consensus without data is just educated speculation.
Thousands of men are prescribed enclomiphene from telehealth clinics with the understanding that it's a "better" alternative to TRT because it preserves the axis. What they're not told: we have no idea what happens when they stop. One week of PK/PD data, then a cliff edge.
Why the Void Exists
The temptation is to frame this as negligence — that researchers or regulators simply forgot. It's not negligence. It's architecture.
The evidence pipeline is designed for initiation:
- Phase I–III trials measure efficacy during treatment
- FDA approval requires demonstrating the drug works — not what happens when it stops
- Post-marketing surveillance tracks adverse events during use
- Meta-analyses aggregate on-treatment data
- Guidelines recommend when to start — rarely when or how to stop
- Pharma funding incentivizes treatment continuation, not cessation research
A 2026 study followed 56.7% of bariatric patients experiencing significant weight regain over 10 years. The researchers measured glucose, lipids, blood pressure, and comorbidity relapse. They did not measure testosterone or any reproductive hormone. Not because it was irrelevant — bariatric patients are disproportionately hypogonadal. Because hormonal outcomes after weight regain aren't part of the measurement architecture. The instruments don't point there.
The same pattern recurs: the eClinicalMedicine GLP-1 discontinuation meta-analysis pooled 18 RCTs and 3,771 patients. It measured weight, HbA1c, blood pressure, lipids. It did not measure testosterone. Not because they lacked the samples. Because it wasn't in the protocol. Because the protocols are designed to measure the drug's target outcome (weight), not the downstream hormonal consequences of that outcome reversing.
What a Monitoring Framework Would Look Like
If we took the patient's question seriously — what happens when I stop? — here is what would need to exist for each treatment modality:
| Treatment | Cessation Monitoring Needed | Current Status |
|---|---|---|
| TRT | T, LH/FSH at 1, 3, 6 months; symptom diary; fertility panel if relevant | Partially exists — withdrawal studies provide timelines |
| hCG | T, LH/FSH at 1, 3 months; INSL3; semen analysis | Pituitary recovery data only — no symptom or long-term data |
| SERMs | T, LH/FSH weekly × 4, then monthly × 6; GnRH pulsatility assessment | Does not exist — 1 week of PK data, then nothing |
| GLP-1 RAs | T, free T, LH/FSH, SHBG at 1, 3, 6, 12 months; weight; metabolic panel; sexual function | Does not exist — weight/metabolic data only |
| Combination | All of the above, stratified by which component is stopped | Does not exist — no RCTs of any kind |
None of this is technically difficult. The assays exist. The patients are already in clinics being monitored on treatment. The only thing that would need to change is continuing to measure after the prescription ends.
The ADT Exception Proves the Rule
There is exactly one context in testosterone medicine where discontinuation science thrives: androgen deprivation therapy for prostate cancer. At AUA 2025, Amorim presented a meta-analysis of prospective trials on testosterone recovery after ADT cessation. The TRANSPORT consortium pooled five randomized trials from the MARCAP group. Recovery profiles are mapped by drug class and duration.
Why does this data exist? Because ADT is intentionally time-limited in many protocols. Oncologists need to know if testosterone recovers so they can assess ongoing cancer risk and quality of life. The clinical question demands exit data, so exit data gets funded.
In hypogonadism treatment, the opposite assumption holds: most treatments are prescribed indefinitely. If the assumption is that patients never stop, nobody designs studies around stopping. But patients do stop — because of cost, side effects, access disruption, pregnancy planning, or simply wanting to know if they still need the drug. They stop without data to guide what happens next.
Three Things That Need to Happen
First, every GLP-1 RA trial enrolling men should measure testosterone, free testosterone, LH, FSH, and SHBG — both during and after treatment. The ATTAIN trials enrolled approximately 1,126 men. Not one had testosterone measured. For a drug class whose most significant secondary benefit may be HPG axis restoration, this is an extraordinary oversight.
Second, a prospective discontinuation registry for secondary hypogonadism. Not one study per treatment — a cross-treatment registry that follows men who stop any modality (TRT, hCG, SERMs, GLP-1 RAs, combinations) with standardized hormone panels, symptom instruments, and metabolic markers at fixed intervals. The cost would be minimal relative to the number of men affected. The data would be transformative.
Third, the DTC clinics that now prescribe enclomiphene, hCG, and testosterone to hundreds of thousands of men have an inadvertent opportunity. Their patients discontinue frequently — because of cost, insurance changes, or supply disruptions. If even one large telehealth platform implemented post-discontinuation hormone monitoring as standard of care, it would generate more cessation data in a year than academic medicine has produced in decades.
The Uncomfortable Truth
The question "What happens when I stop?" has been adequately studied for one treatment modality (TRT), partially studied for two (AAS recovery, hCG), and not studied at all for three (SERMs, GLP-1 RAs, combination therapy). The treatments with the most patients and the most growth have the least data on cessation.
This isn't a knowledge gap that will close on its own. The incentive structures that created it are still operating. Pharma funds initiation trials. Regulators require initiation data. Clinics bill for active treatment. Nobody has a financial incentive to study what happens when the billing stops.
The patient asks: what happens when I stop?
Medicine answers: we built you an on-ramp.
The exit isn't their problem.